Selected article for: "ii activity and immune response"
Author: Govender, Nalini; Khaliq, Olive P.; Moodley, Jagidesa; Naicker, Thajasvarie
Title: Insulin resistance in COVID-19 and diabetes
  • Cord-id: t9604k86
  • Document date: 2021_4_8
    • ID: t9604k86
    Snippet: BACKGROUND: The epidemiology of COVID-19 and its association with cardiometabolic disorders is poorly understood. This is a narrative review that investigates the effects of COVID-19 infection on insulin resistance in patients with diabetes. METHODS: An online search of all published literature was done via PubMed and Google Scholar using the MeSH terms “COVID-19,” “SARS-CoV-2,” “coronavirus,” “insulin resistance,” and “diabetes.” Only articles that were directly applicable t
    Document: BACKGROUND: The epidemiology of COVID-19 and its association with cardiometabolic disorders is poorly understood. This is a narrative review that investigates the effects of COVID-19 infection on insulin resistance in patients with diabetes. METHODS: An online search of all published literature was done via PubMed and Google Scholar using the MeSH terms “COVID-19,” “SARS-CoV-2,” “coronavirus,” “insulin resistance,” and “diabetes.” Only articles that were directly applicable to insulin resistance in COVID-19 and diabetes was reviewed. RESULTS: Current data shows an increased risk of mortality in patients with diabetes and COVID-19 compared to those without diabetes. COVID-19 triggers insulin resistance in patients, causing chronic metabolic disorders that were non-existent prior to infection. CONCLUSION: Patients with diabetes are more susceptible to COVID-19 infection than those without diabetes. ACE2 expression decreases with infection, exaggerating Ang II activity with subsequent insulin resistance development, an exaggerated immune response and severe SARS-COV-2 infection.

    Search related documents:
    Co phrase search for related documents
    • ace ii receptor and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8
    • ace ii receptor and acute lung injury: 1, 2, 3, 4
    • ace ii receptor and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • ace ii receptor and acute respiratory syndrome sars: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • ace ii receptor and adipose tissue: 1, 2
    • ace inhibitor and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • ace inhibitor and acute lung injury: 1, 2, 3, 4
    • ace inhibitor and acute respiratory distress syndrome: 1, 2, 3, 4, 5
    • ace inhibitor and acute respiratory syndrome sars: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • ace inhibitor and adipose tissue: 1
    • acute ards respiratory distress syndrome and adipose tissue: 1, 2, 3, 4
    • acute diabetes and adipose tissue: 1
    • acute lung injury and adaptative immune response: 1
    • acute lung injury and adipose tissue: 1, 2
    • acute respiratory distress syndrome and adaptative immune response: 1
    • acute respiratory distress syndrome and adipose tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome sars and adaptative immune response: 1
    • acute respiratory syndrome sars and adipose tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome sars and adipose tissue release: 1